# Page 112 Audit — Biographic & Disclosure: Wanner (cont), Wilkens, Zoungas (5 Spans)

## Page Identity
- **PDF page**: S111 (Biographic and Disclosure Information — www.kidney-international.org)
- **Content**: Wanner bio conclusion + COI; Katy Wilkens bio (renal dietitian, no COI); Sophia Zoungas bio + COI — **last biographic page**
- **Clinical tier**: T3 (Informational — author biographies and disclosures)
- **Job ID**: df538e50-0170-4ef8-862d-5b0a7c48e4ff
- **Disagreement flag**: NO

## Extraction Summary
| Metric | Value |
|--------|-------|
| Total spans | 5 |
| T1 (Patient Safety) | 2 |
| T2 (Clinical Accuracy) | 3 |
| T3 (Informational) | 0 |
| Channels present | B (Drug Dictionary), F (NuExtract LLM) |
| Tier accuracy | 0% (0/5) |
| Disagreements | 0 |
| Review Status | PENDING: 5 |
| Audit Date | 2026-02-25 (revised) |
| Cross-Check | 2026-02-25 — counts verified against raw extraction data |

## All Spans

| # | Text | Channel | Conf | Tier | Correct Tier | Issue |
|---|------|---------|------|------|-------------|-------|
| 1 | "empagliflozin" | B | 100% | T1 | T3 | Drug name from Wanner bio — research description |
| 2 | "empagliflozin" | B | 100% | T1 | T3 | Duplicate — same drug from same context |
| 3 | `<!-- PAGE 112 -->` | F | 90% | T2 | NOISE/BUG | **HTML artifact (12th occurrence)** |
| 4 | "rewarding to offer information that can lead others to a healthier future." | F | 90% | T2 | T3 | Wilkens bio — motivational statement |
| 5 | "KGW declared no competing interests." | F | 90% | T2 | T3 | Wilkens — no COI declaration |

### B Channel "empagliflozin" ×2 as T1
Both B spans come from Wanner's bio: "sodium-glucose cotransporter-2 inhibitor **empagliflozin** impacting cardiovascular and kidney disease outcomes." This is a description of research contributions, not a prescribing instruction. The B channel's 100% confidence + T1 means Accept is gated (2 T1 spans block).

### Biographic Section Complete (Pages 107-112)
| Page | Spans | T1 | T2 | Authors |
|------|-------|----|----|---------|
| 107 | 11 | 0 | 11 | de Boer, Rossing, Caramori (start) |
| 108 | 7 | 0 | 7 | Caramori (cont), Chan, Heerspink (start) |
| 109 | 2 | 0 | 2 | Hurst, Khunti, Liew, Michos (start) |
| 110 | 4 | 0 | 4 | Michos (cont), Navaneethan, Olowu, Sadusky (start) |
| 111 | 6 | 1 | 5 | Sadusky (cont), Tandon, Tuttle, Wanner (start) |
| 112 | 5 | 2 | 3 | Wanner (cont), Wilkens, Zoungas |
| **Total** | **35** | **3** | **32** | **14 Work Group + 2 patient reps** |

## PDF Source Content
- **Christoph Wanner** (continued): 4D study (2005); SGLT2i empagliflozin research; 850+ publications; ERA Registry chair; ERA president 2020-2024; doctor honoris causa Charles University Prague
- **Wanner COI**: Bayer, Boehringer Ingelheim, Genzyme-Sanofi, Gilead, GSK, Idorsia, MSD, Tricida (board); Akebia, Amicus, Chiesi, Vifor (consultancy); Amgen, Amicus, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Fresenius, Genzyme-Sanofi, MSD, Novartis, Takeda (speaker)
- **Katy G. Wilkens, MS, RD**: Retired renal dietitian at Northwest Kidney Centers (45 years); 2000+ dialysis/CKD patients; author of renal nutrition textbook chapter; Clyde Shields Award, Susan Knapp Award (2013), Joel Kopple Award (2019), AAKP Medal of Excellence (2021). **No COI.**
- **Sophia Zoungas, MBBS, FRACP, PhD**: Head of Monash University School of Public Health; endocrinologist; Australian Diabetes Society president 2016-2018; 250+ publications
- **Zoungas COI**: AstraZeneca*, Boehringer Ingelheim*, MSD Australia*, Novo Nordisk*, Sanofi* (advisory board); Servier* (speaker); Eli Lilly* (expert committee)

## Decision Recommendation
**ACCEPT** — Zero clinical safety risk. Final biographic page with author bios and COI disclosures.

## Audit Metadata
- **Audited**: 2026-02-24
- **Method**: Playwright browser UI (Phase 2B Page Browse)
- **Auditor**: Claude (automated)
- **Page in sequence**: 112 of 126
